Taken together, targeting the HSP family of molecular chaperones is a valid therapeutic approach to overcome persistent AR signaling in advanced prostate cancer, although concerns remain about the therapeutic window and tolerability of such HSP-targeting strategies (30, 34). This evidence concerns the gene HSP90B2P and prostate cancer.